14. Oncología - Sociedad Española de Farmacia Hospitalaria

1224 FARMACIA HOSPITALARIAtin-Induced Emesis. Oncology 1997; 54:1-6.94. Munsted K, Muller H, Blaut-Eckmeyer E, et al.Role of Dexamethasone Dosage in Combinationwith 5-HT3 Antagonists for Prophylaxis of AcuteChemotherapy-Induced Nausea and Vomiting. BrJ Cancer 1999; 79:637-639.95. Italian Group for Antiemetic Research. Doubleblind,dose-finding study of four intravenous dosesof dexamethasone in the prevention of cisplatin-inducedacute emesis. J Clin Oncol 1998 Sep;16(9):2937-42.96. Navari RM, Madajewicz S, Anderson N, et al. OralOndansetron for the Control od Cisplatin-InducedDelayed Emesis: A Large, Bouble-Blind, RandomizedComparative Trial of Ondansetron VersusPlacebo. J Clin Oncol 1995; 13:2408-2416.97. Matsui K, Fukuoka M, Takada M, et al. RandomizedTrial for the Prevention of Delayed Emesis inPatients Receiving High-Dose Cisplatin. Br J Cancer1996; 73:217-222.98. Gandara DH, Harvey Wh, Monaghan GG, et al.The Delayed Emesis Syndrome From Cisplatin:Phase III Evaluation of Ondansetron Versus Placebo.Sem Oncol 1992; 19(4 supp 10):67-71.99. Italian Group for Antiemetic Research. DelayedEmesis Induced by Moderately Emetogenic Chemotherapy:Do we Need to Treat all Patients. AnnOncol 1997; 8:561-567.100. Kris Mg, Gralla RJ, Tyson Lb, et al. ControllinfDelayed Vomiting: Double-Blind, RandomizedTrial Comparing Placebo, Dexamethasone Alone,and Metoclopramide Plus Dexamethasone in PatientsReciving Cisplatin. J Clin Oncol 1989; 7:108-114.101. Navari RM, Reinhardt RR, Gralla RJ, et al. Reductionof cisplatin-induced emesis by a selective neurokinin-1-receptorantagonist. L-754,030 AntiemeticTrials Group. N Engl J Med 1999 Jan 21;340(3): 190-5.102. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomizedphase II study of the neurokinin 1 receptor antagonistCJ-11,974 in the control of cisplatin-inducedemesis. J Clin Oncol 1999 Jan; 17(1):338-43.103 Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparisonof L-758,298, a prodrug for the selectiveneurokinin-1 antagonist, L-754,030, with ondansetronfor the prevention of cisplatin-induced emesis.Eur J Cancer 2001 May; 37(7):835-42.104. Campos D, Pereira JR, Reinhardt RR, et al. Preventionof cisplatin-induced emesis by the oralneurokinin-1 antagonist, MK-869, in combinationwith granisetron and dexamethasone or with dexamethasonealone. J Clin Oncol 2001 Mar 15; 19(6):1759-67.105. Koo WH and Ang PT. Role of Maintenance OralDexamethasone in Prophylaxis of Delayed EmesisCaused by Moderately Emetogenic Chemotherapy.Ann Oncol 1996; 7:71-74.106. Kaizer L, Warr D, Hoskins P, et al. Effect on Scheduleand Maintenance on the Antiemetic Efficacyof Ondansetron Combined with Dexamethasonein Acute and Delayed Nausea and Emesis in PatientsReceiving Moderately Emetogenic Chemotherapy:A Phase III Trial by the National CancerInstitute of Canada Clinical Trials Group. J ClinOncol 1994; 12:1050-1057.107. Pater JL, Lofters WS, Zee B, et al. The Role of the5-HT3 Antagonists Ondansetron and Dolasetronin the Control of Delayed Onset Nausea and Vomitingin Patients Receiving Moderately EmetogenicChemotherapy. Ann Oncol 1997; 8:181-185(223).108. The Italian Group for Antiemetic Research. Dexamethasonealone or in combination with ondansetronfor the prevention of delayed nauseaand vomiting induced by chemotherapy. N Engl JMed. 2000 May 25; 342(21): 1554-9.109. Lebeau B, Depierre A, Giovannini M, et al. The efficacyof a combination of ondansetron, methylprednisoloneand metopimazine in patients previouslyuncontrolled with a dual antiemetictreatment in cisplatin-based chemotherapy. TheFrench Ondansetron Study Group. Ann Oncol1997 Sep; 8(9):887-92.110. Llop JC, Mateu J, Llorente A. Extravasación defármacos citostáticos: diagnóstico, evolución y tratamiento.Med Clin (Barc) 1993; 101:105-109.111. Gordon Li, Hanh MB, Lewis V. Prophylaxis andmanagement of chemotherapy extravasations.Curr Concepts Oncol 1985; 7:18-22.112. Johnston-Early A, Cohen MH. Mitomycin C-inducedskin ulceration remote from infusion site.Cancer Treat Rep 1981; 65:529.113. Hardwood KV, Aisner J. Treatment of chemotherapyextravasation: current status. Cancer TreatRep 1984; 68:939-945.114. Prat A, coord. Recomanacions per a la manipulacióde medicaments antineoplàsics als centres hos-